Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Conditions

• Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• OSI-774: erlotinib, TarcevaTM — DRUG
  150 mg, 100 mg and 25 mg tablets

Study Details

The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer. This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose should be given to patients with cancer has been completed. The purpose of this research study is to see whether this experimental treatment, called OSI-774, can cause a type of non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company called Genentech, and is being done at Memorial Hospital, as well as other cancer centers around the country interested in developing new drugs for the treatment of this type of cancer.

Key Dates

First listed

Jan 11, 2008

Start date

Mar 31, 2002

Status verified

Oct 2023

Primary completion

Feb 28, 2013

Completion

Feb 28, 2013

Study Design

Enrollment

81 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: 1 - OSI-774

Primary Outcome Measure

Overall Objective Response of OSI-774 [ Time Frame: 53 weeks ]

Locations (1)

Find similar trials in New York, NY